CytomX Therapeutics, Inc.
CTMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001501989
No open-market purchases or sales by CytomX Therapeutics, Inc. insiders were filed in the last 90 days; 178 institutions reported holding it in 13F filings for Q2 2026, worth $799.0M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding CytomX Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 74 | 2 | 69 | −3 |
| Shares | 50.7M | 1.19M | 51.2M | +1.70M (+3.4%) |
| Value | $61.9M | $1.46M | $60.4M | +$19.8K (0.0%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held CytomX Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Prosight Management, LP | 3,022,109 | $3.57M | 0.90% |
| BlackRock, Inc. | 1,168,566 | $1.38M | 0.00% |
| Altium Capital Management LP | 915,000 | $1.08M | 0.32% |
| Woodline Partners LP | 393,832 | $464.7K | 0.00% |
| Virtu Financial LLC | 88,518 | $104.0K | 0.01% |
| US Bancorp | 33,792 | $39.9K | 0.00% |
| AJOVista, LLC | 33,121 | $39.1K | 0.17% |
| HRT Financial LP | 26,840 | $31.0K | 0.00% |
| EP Wealth Advisors, LLC | 10,432 | $12.3K | 0.00% |
| Peregrine Asset Advisers, Inc. | 10,000 | $11.8K | 0.00% |
Sold out (13)
Institutions that held CytomX Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| RTW Investments, LP | 1,200,002 | $1.46M |
| Superstring Capital Management LP | 1,151,518 | $1.40M |
| Ghost Tree Capital, LLC | 300,000 | $366.0K |
| Gsa Capital Partners LLP | 229,093 | $279.0K |
| Candriam Luxembourg S.C.A. | 210,027 | $256.2K |
| Squarepoint Ops LLC | 198,840 | $242.6K |
| Two Sigma Advisers, LP | 158,400 | $193.2K |
| LMR Partners LLP | 15,046 | $18.4K |
| Simplex Trading, LLC | 3,891 | $4.00K |
| Whittier Trust Co | 2,200 | $2.68K |
| Rhumbline Advisers | 1,291 | $1.57K |
| Innealta Capital, LLC | 2 | $2 |
| Royal Bank of Canada | 248 | $0 |
Not filed for Q3 2024 yet (2)
Institutions that held CytomX Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 1,139,029 | $1.39M |
| Susquehanna Fundamental Investments, LLC | 54,422 | $66.4K |